Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 continues to demonstrate a favorable safety and tolerability profile...
Hence then, the article about enliven therapeutics announces updated positive data from phase 1 clinical trial of elvn 001 in cml and oral presentation at the eha 2025 congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress )
Also on site :
- Thursday: What races the AP has not yet called in contests for Senate and governor
- What to Expect From Best Buy's Black Friday and Cyber Monday Sales This Year
- LEGO’s 2026 Holiday Ad Stars Daft Punk, E.T. & ‘KPop Demon Hunters’: Shop the Sets Featured in the Video